ZA200800555B - IL-1² binding antibodies and fragments thereof - Google Patents
IL-1² binding antibodies and fragments thereofInfo
- Publication number
- ZA200800555B ZA200800555B ZA200800555A ZA200800555A ZA200800555B ZA 200800555 B ZA200800555 B ZA 200800555B ZA 200800555 A ZA200800555 A ZA 200800555A ZA 200800555 A ZA200800555 A ZA 200800555A ZA 200800555 B ZA200800555 B ZA 200800555B
- Authority
- ZA
- South Africa
- Prior art keywords
- fragments
- binding antibodies
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69283005P | 2005-06-21 | 2005-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200800555B true ZA200800555B (en) | 2009-09-30 |
Family
ID=37595818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200800555A ZA200800555B (en) | 2005-06-21 | 2008-01-18 | IL-1² binding antibodies and fragments thereof |
Country Status (24)
Country | Link |
---|---|
US (11) | US7531166B2 (fr) |
EP (5) | EP1899378B1 (fr) |
JP (2) | JP4931919B2 (fr) |
KR (3) | KR20140139618A (fr) |
CN (2) | CN101228188A (fr) |
AT (1) | ATE446972T1 (fr) |
AU (1) | AU2006262179B2 (fr) |
BR (1) | BRPI0612273C1 (fr) |
CA (2) | CA2873914A1 (fr) |
CY (3) | CY1109715T1 (fr) |
DE (1) | DE602006010072D1 (fr) |
DK (4) | DK1899378T3 (fr) |
ES (5) | ES2569917T3 (fr) |
HK (3) | HK1158218A1 (fr) |
HU (1) | HUE029021T2 (fr) |
IL (2) | IL188094A (fr) |
MX (2) | MX348154B (fr) |
NZ (1) | NZ565138A (fr) |
PL (4) | PL2322552T3 (fr) |
PT (3) | PT1899378E (fr) |
RU (1) | RU2518295C2 (fr) |
SI (4) | SI1899378T1 (fr) |
WO (1) | WO2007002261A2 (fr) |
ZA (1) | ZA200800555B (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2569917T3 (es) * | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
BRPI0617830B8 (pt) | 2005-10-26 | 2021-05-25 | Novartis Ag | uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
CA2660519A1 (fr) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Therapie locale de troubles inflammatoires des voies aeriennes inferieures avec des inhibiteurs de cytokine proinflammatoire |
CA2839162A1 (fr) * | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Methodes de traitement de maladies associees a l'interleukine-1-.beta. |
US7695718B2 (en) * | 2006-12-20 | 2010-04-13 | Xoma Technology Ltd. | Methods for the treatment of IL-1β related diseases |
EP2468301A1 (fr) | 2007-05-29 | 2012-06-27 | Novartis AG | Nouvelles indications pour une thérapie anti-IL-1-bêta |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
CA2710252C (fr) | 2007-12-20 | 2017-03-28 | Xoma Technology Ltd. | Procedes pour le traitement de la goutte |
JP5607613B2 (ja) * | 2008-06-06 | 2014-10-15 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | 関節リウマチの治療のための方法 |
US8377429B2 (en) * | 2008-09-05 | 2013-02-19 | Xoma Technology Ltd. | Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof |
EP3011953A1 (fr) * | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Formulations stabilisées de molécules de liaison d'antigène monodomaines |
AU2010208637A1 (en) * | 2009-01-29 | 2011-08-04 | Abbvie Inc. | IL-1 binding proteins |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2403873A1 (fr) | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Nouveaux complexes dimères de liaison antigénique, méthodes d'obtention/non obtention et leurs utilisations |
EP2427209A1 (fr) * | 2009-05-06 | 2012-03-14 | Novartis AG | Thérapie par combinaison d'anticorps anti-il1- |
CA2763161A1 (fr) | 2009-05-29 | 2010-12-02 | Xoma Technology Ltd. | Utilisations d'anticorps il-1.beta. de fragments de liaison de ceux-ci en relation avec des evenements et des maladies cardiovasculaires |
US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
EP3438126B1 (fr) | 2009-09-03 | 2020-08-19 | Ablynx N.V. | Formulations stables de polypeptides et leurs utilisations |
CA2772945A1 (fr) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Procedes de criblage |
US8398966B2 (en) * | 2009-10-15 | 2013-03-19 | Abbvie Inc. | IL-1 binding proteins |
DE102009047243A1 (de) | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
MX337586B (es) * | 2010-05-07 | 2016-03-11 | Xoma Us Llc | Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta. |
AU2011299066A1 (en) | 2010-09-10 | 2013-03-21 | Apexigen, Inc. | Anti-IL-1 beta antibodies and methods of use |
BR112013020259A2 (pt) * | 2011-02-08 | 2018-05-15 | Abbvie Inc | tratamento de osteoartrite e dores |
US20140308294A1 (en) | 2011-04-15 | 2014-10-16 | Merck Patent Gmbh | Anti-IL-1R1 Inhibitors For Use in Cancer |
US10206951B2 (en) | 2011-06-03 | 2019-02-19 | Mesoblast, Inc. | Methods of treating multiple sclerosis using STRO-1+ and TNAP+ multipotential cells |
US9707272B2 (en) | 2011-07-12 | 2017-07-18 | Universitat Zurich | Method for the treatment of acne by administering IL-1β antibody |
TWI461192B (zh) * | 2011-07-20 | 2014-11-21 | Twi Biotechnology Inc | 降低血脂異常病患之糖化血色素的醫藥組成物 |
DE102011083595A1 (de) * | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
AR088083A1 (es) | 2011-09-30 | 2014-05-07 | Novartis Ag | USO DE ANTICUERPOS DE UNION A IL-1b |
WO2013096516A1 (fr) * | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Méthodes de traitement de l'acné |
PL2623604T3 (pl) * | 2012-02-02 | 2015-07-31 | Baylor College Medicine | Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów |
US10167335B2 (en) | 2012-02-13 | 2019-01-01 | Agency For Science, Technology And Research | IL-1β neutralizing human monoclonal antibodies |
CN104583238A (zh) * | 2012-08-31 | 2015-04-29 | 阿尔金-X有限公司 | 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法 |
EP2914287B1 (fr) * | 2012-11-05 | 2020-03-18 | Delenex Therapeutics AG | Éléments de liaison vers il-1 bêta |
WO2014095808A1 (fr) * | 2012-12-17 | 2014-06-26 | Delenex Therapeutics Ag | Anticorps contre il-1 bêta |
EP4050019A1 (fr) * | 2013-02-15 | 2022-08-31 | R-Pharm International, LLC | Composition d'inhibiteur d'il-1beta et utilisation correspondante |
EP3003356B1 (fr) * | 2013-05-31 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Antagonistes de l'il-1 pour l'ultilisation dans le traitement de la maladie d'alzheimer |
CN104341501B (zh) * | 2013-07-29 | 2019-08-30 | 上海睿智化学研究有限公司 | 抗IL-1β人源化单克隆抗体及其制备方法和应用 |
EP4223874A3 (fr) * | 2013-12-26 | 2023-09-27 | Mitsubishi Tanabe Pharma Corporation | Anticorps monoclonal humain neutralisant anti-il-33 |
WO2016008851A1 (fr) * | 2014-07-14 | 2016-01-21 | Boehringer Ingelheim International Gmbh | Anticorps anti-il-1b |
EA036237B1 (ru) | 2015-05-18 | 2020-10-16 | Байер Фарма Акциенгезельшафт | Режим приема селективного модулятора рецептора прогестерона (sprm) |
JP6501650B2 (ja) * | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | ヒト抗il−33中和モノクローナル抗体 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CN108218978B (zh) * | 2016-12-13 | 2020-05-12 | 沈阳何氏眼产业集团有限公司 | 一种重组白细胞介素18及其制备方法与应用 |
WO2018112256A1 (fr) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1 |
JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのIL−1β結合性抗体 |
WO2018235056A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer |
CN111107875A (zh) | 2017-08-31 | 2020-05-05 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
BR112020004903A2 (pt) | 2017-09-13 | 2020-09-15 | Novartis Ag | uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica |
BR112020008888A2 (pt) | 2017-11-16 | 2020-10-20 | Novartis Ag | terapias de combinação |
GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
EP3836954A1 (fr) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
WO2020039401A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons |
WO2020106754A1 (fr) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques |
WO2020128613A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | Utilisation d'anticorps de liaison à il-1bêta |
WO2021116789A1 (fr) | 2019-12-09 | 2021-06-17 | Novartis Ag | Anticorps anti-interleukine 1 bêta pour le traitement de la drépanocytose |
WO2021119482A1 (fr) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
TWI793503B (zh) * | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | 抗IL-1β抗體 |
US20230068783A1 (en) * | 2020-01-21 | 2023-03-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Agents that interfere with il-1beta receptor signalling |
WO2022167916A1 (fr) | 2021-02-03 | 2022-08-11 | Novartis Ag | Utilisation d'anticorps se liant à l'il-1b pour le traitement de troubles neuro-inflammatoires |
CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US493543A (en) * | 1893-03-14 | Lap-ring | ||
US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (fr) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipides et composés tensio-actifs en phase aqueuse |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0142641B1 (fr) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Moyen et produit pour le diagnostic et la thérapie de tumeurs ainsi que pour le traitement de déficiences du système immunitaire cellulaire et humoral |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
EP0569687B1 (fr) | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Séquences de cADN de l'IL-1 humaine codant pour des protéines biologiquement actives de l'IL-1 humaine |
DE3587669T2 (de) | 1984-05-18 | 1994-03-31 | New England Medical Center Inc | Menschliche IL-1-cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren. |
US4762914A (en) | 1984-05-18 | 1988-08-09 | Auron Philip E | Truncated protein of interleukin-1 |
US5077219A (en) | 1984-05-18 | 1991-12-31 | New England Medical Center Hospitals | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
US5484887A (en) | 1984-06-19 | 1996-01-16 | Immunex Corporation | Homogeneous interleukin 1 |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5122459A (en) | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US5474899A (en) | 1987-05-13 | 1995-12-12 | Cistron Biotechnology, Inc. | Selective immunoassay for IL-1 β |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5077218A (en) * | 1988-05-05 | 1991-12-31 | Oregon Lions Sight And Hearing Foundation Inc. | Eye transport apparatus |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
EP0364778B1 (fr) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Anticorps contre l'interleukine-1 bêta |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE69032251T2 (de) | 1989-02-27 | 1998-08-13 | New England Medical Center Inc | Il-1, dessen biologische aktivität inhibiert ist |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2090473A1 (fr) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Recombinaison homologue dans des cellules mammaliennes |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
WO1993011236A1 (fr) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
WO1994000470A1 (fr) * | 1992-06-30 | 1994-01-06 | The Wistar Institute Of Anatomy And Biology | BANQUES D'ADNc D'EMBRYONS DE SOURIS EN COURS DE DEVELOPPEMENT |
US6664114B1 (en) | 1992-08-03 | 2003-12-16 | Sapidyne Instruments, Inc. | Solid phase assay for detection of ligands |
ES2151541T3 (es) | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
WO1995001997A1 (fr) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME |
US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
BR9509201A (pt) | 1994-09-09 | 1997-12-30 | Takeda Chemical Industries Ltd | Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada |
JPH10507637A (ja) * | 1994-10-20 | 1998-07-28 | メルク エンド カンパニー インコーポレーテッド | インターロイキン−1β欠損トランスジェニック動物 |
EP0791359A4 (fr) * | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | Remede contre des maladies provoquees par la production d'il-6 |
ATE212545T1 (de) | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
PT831787E (pt) | 1995-06-07 | 2002-02-28 | Alkermes Inc | Composicao para libertacao sustentada da hormona de crescimento humano |
US5817476A (en) | 1995-06-07 | 1998-10-06 | Genetics Institute, Inc. | Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
US6004788A (en) | 1995-07-18 | 1999-12-21 | Diversa Corporation | Enzyme kits and libraries |
US6455254B1 (en) | 1995-07-18 | 2002-09-24 | Diversa Corporation | Sequence based screening |
US6030779A (en) | 1995-07-18 | 2000-02-29 | Diversa Corporation | Screening for novel bioactivities |
US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
US6168919B1 (en) | 1996-07-17 | 2001-01-02 | Diversa Corporation | Screening methods for enzymes and enzyme kits |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
US6489145B1 (en) | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
US6368798B1 (en) | 1995-12-07 | 2002-04-09 | Diversa Corporation | Screening for novel bioactivities |
US6344328B1 (en) | 1995-12-07 | 2002-02-05 | Diversa Corporation | Method for screening for enzyme activity |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
WO1997034631A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
EA001866B1 (ru) * | 1996-10-31 | 2001-10-22 | Апплайд Резеч Системз Арс Холдинг Н.В. | ПЕПТИД, СПОСОБНЫЙ СВЯЗЫВАТЬСЯ С ИНТЕРЛЕЙКИН-1-beta-КОНВЕРТИРУЮЩИМ ФЕРМЕНТОМ (ICE), И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ЕГО ОСНОВЕ |
AU7103198A (en) * | 1997-04-21 | 1998-11-13 | Schering Corporation | Mammalian cytokines; related reagents and methods |
KR20010052894A (ko) | 1998-06-17 | 2001-06-25 | 맥시겐, 인크. | 목적하는 특성을 보유한 폴리뉴클레오티드를 생성하는 방법 |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
US20010053764A1 (en) | 2000-05-12 | 2001-12-20 | Sims John E. | Interleukin-1 inhibitors in the treatment of diseases |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US6864047B2 (en) | 2001-03-29 | 2005-03-08 | Mayo Foundation For Medical Education And Research | IL1-β: a new target for myeloma therapy |
US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
WO2003010282A2 (fr) * | 2001-07-26 | 2003-02-06 | Eli Lilly And Company | Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b)) |
JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
JP2005522986A (ja) | 2001-10-19 | 2005-08-04 | ジェネンテック・インコーポレーテッド | 炎症性腸疾患の診断と治療のための組成物と方法 |
US6673552B2 (en) | 2002-01-14 | 2004-01-06 | Diversa Corporation | Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps |
JP2005518802A (ja) | 2002-02-28 | 2005-06-30 | イーライ・リリー・アンド・カンパニー | 抗インターロイキン−1ベータ類縁体 |
US7572770B2 (en) | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
ATE549033T1 (de) | 2002-09-06 | 2012-03-15 | Amgen Inc | Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper |
CA2503886A1 (fr) | 2002-11-01 | 2004-05-13 | Alk-Abello A/S | Variants de proteines de recombinaison |
US7541033B2 (en) * | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
US20040266993A1 (en) | 2003-06-30 | 2004-12-30 | Evans Glen A. | Non-immunoglobulin binding polypeptides |
US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
US20050152850A1 (en) | 2004-01-09 | 2005-07-14 | Engebretson Steven P. | Methods and compositions for facilitating metabolic control |
US7732478B2 (en) | 2004-01-09 | 2010-06-08 | The Trustees Of Columbia University In The City Of New York | Methods for facilitating metabolic control |
WO2005084696A1 (fr) | 2004-03-08 | 2005-09-15 | Universita'degli Studi Di Milano | Procedes et agents permettant de maitriser l'inflammation intestinale et l'immunite mucosale au moyen d'agents interagissant avec tir8/sigirr |
EP1576952A1 (fr) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Microsphères d'hydrogel avec un profil amélioré de libération |
US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
ES2395953T3 (es) | 2005-01-26 | 2013-02-18 | Amgen Fremont Inc. | Anticuerpos frente a interleucina-1 beta |
ES2569917T3 (es) | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
FR2895611B1 (fr) | 2005-12-23 | 2008-02-22 | Thales Sa | Architecture et procede pour controler le transfert d'informations entre utilisateurs |
US8479265B2 (en) * | 2008-07-02 | 2013-07-02 | Oracle International Corporation | Usage based authorization |
-
2006
- 2006-06-21 ES ES10179089.7T patent/ES2569917T3/es active Active
- 2006-06-21 AU AU2006262179A patent/AU2006262179B2/en active Active
- 2006-06-21 DK DK06773749.4T patent/DK1899378T3/da active
- 2006-06-21 ES ES10179088T patent/ES2391334T3/es active Active
- 2006-06-21 PT PT06773749T patent/PT1899378E/pt unknown
- 2006-06-21 ES ES06773749T patent/ES2335232T3/es active Active
- 2006-06-21 CN CNA2006800265519A patent/CN101228188A/zh active Pending
- 2006-06-21 DK DK10179089.7T patent/DK2322552T3/en active
- 2006-06-21 CA CA2873914A patent/CA2873914A1/fr not_active Abandoned
- 2006-06-21 ES ES09174190.0T patent/ES2439709T3/es active Active
- 2006-06-21 SI SI200630518T patent/SI1899378T1/sl unknown
- 2006-06-21 US US11/472,813 patent/US7531166B2/en active Active
- 2006-06-21 SI SI200631432T patent/SI2314623T1/sl unknown
- 2006-06-21 EP EP06773749A patent/EP1899378B1/fr active Active
- 2006-06-21 EP EP10179089.7A patent/EP2322552B1/fr active Active
- 2006-06-21 PT PT10179088T patent/PT2314623E/pt unknown
- 2006-06-21 RU RU2008102135/10A patent/RU2518295C2/ru active
- 2006-06-21 DE DE602006010072T patent/DE602006010072D1/de active Active
- 2006-06-21 SI SI200631713T patent/SI2163562T1/sl unknown
- 2006-06-21 CN CN201210157441.3A patent/CN102775493B/zh active Active
- 2006-06-21 BR BRPI0612273A patent/BRPI0612273C1/pt active IP Right Grant
- 2006-06-21 KR KR1020147030783A patent/KR20140139618A/ko not_active Application Discontinuation
- 2006-06-21 EP EP09174190.0A patent/EP2163562B1/fr active Active
- 2006-06-21 NZ NZ565138A patent/NZ565138A/en unknown
- 2006-06-21 ES ES16154804T patent/ES2827247T3/es active Active
- 2006-06-21 CA CA2612760A patent/CA2612760C/fr active Active
- 2006-06-21 PL PL10179089T patent/PL2322552T3/pl unknown
- 2006-06-21 KR KR1020137015781A patent/KR101502920B1/ko active IP Right Grant
- 2006-06-21 PL PL10179088T patent/PL2314623T3/pl unknown
- 2006-06-21 PT PT91741900T patent/PT2163562E/pt unknown
- 2006-06-21 MX MX2015004669A patent/MX348154B/es unknown
- 2006-06-21 PL PL06773749T patent/PL1899378T3/pl unknown
- 2006-06-21 HU HUE10179089A patent/HUE029021T2/en unknown
- 2006-06-21 AT AT06773749T patent/ATE446972T1/de active
- 2006-06-21 SI SI200632052A patent/SI2322552T1/sl unknown
- 2006-06-21 WO PCT/US2006/024261 patent/WO2007002261A2/fr active Application Filing
- 2006-06-21 PL PL09174190T patent/PL2163562T3/pl unknown
- 2006-06-21 EP EP10179088A patent/EP2314623B1/fr active Active
- 2006-06-21 DK DK09174190.0T patent/DK2163562T3/da active
- 2006-06-21 EP EP16154804.5A patent/EP3056511B1/fr active Active
- 2006-06-21 DK DK10179088.9T patent/DK2314623T3/da active
- 2006-06-21 JP JP2008518374A patent/JP4931919B2/ja active Active
- 2006-06-21 KR KR1020087001520A patent/KR101366450B1/ko active IP Right Grant
- 2006-06-21 MX MX2007016032A patent/MX2007016032A/es active IP Right Grant
-
2007
- 2007-12-12 IL IL188094A patent/IL188094A/en active IP Right Grant
-
2008
- 2008-01-18 ZA ZA200800555A patent/ZA200800555B/xx unknown
- 2008-07-18 US US12/218,997 patent/US7695717B2/en active Active
- 2008-07-18 US US12/218,914 patent/US7582742B2/en active Active
-
2009
- 2009-05-11 US US12/464,006 patent/US7829093B2/en active Active
- 2009-05-11 US US12/463,741 patent/US7744865B2/en active Active
- 2009-05-11 US US12/464,061 patent/US7829094B2/en active Active
- 2009-05-11 US US12/463,844 patent/US7744866B2/en active Active
- 2009-05-12 US US12/464,381 patent/US7943121B2/en active Active
- 2009-05-12 US US12/464,323 patent/US7988968B2/en active Active
- 2009-12-09 IL IL202630A patent/IL202630A/en active IP Right Grant
-
2010
- 2010-01-05 CY CY20101100017T patent/CY1109715T1/el unknown
- 2010-07-27 HK HK11112428.4A patent/HK1158218A1/zh unknown
- 2010-07-27 HK HK11111525.8A patent/HK1157351A1/xx unknown
- 2010-07-27 HK HK10107181.2A patent/HK1140781A1/xx unknown
-
2011
- 2011-05-17 US US13/109,680 patent/US8377442B2/en active Active
- 2011-08-23 JP JP2011181463A patent/JP2011254835A/ja active Pending
-
2012
- 2012-09-28 CY CY20121100891T patent/CY1113153T1/el unknown
-
2013
- 2013-01-11 US US13/739,707 patent/US9206252B2/en active Active
- 2013-12-16 CY CY20131101132T patent/CY1114851T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200800555B (en) | IL-1² binding antibodies and fragments thereof | |
NZ596295A (en) | Anti-5T4 antibodies and uses thereof | |
WO2006113546A3 (fr) | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas | |
RS54133B1 (en) | ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES | |
AU2002217010A1 (en) | Peptides, the production and use thereof for binding immunoglobulins | |
NZ598770A (en) | Monoclonal antibodies | |
WO2005051998A3 (fr) | Anticorps | |
IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
WO2003011898A3 (fr) | Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations | |
WO2004106367A3 (fr) | Antigenes d'enterococcus | |
WO2006127822A3 (fr) | Polypeptides associes au domaine 1 de scytovirine | |
ATE449177T1 (de) | Staphylococcus epidermidis antigene | |
EP2098594A4 (fr) | Molecule d'acide nucleique capable de se lier a un anticorps igg derive du lapin | |
WO2009083968A8 (fr) | Nouvelle protéine | |
WO2006123157A3 (fr) | Proteine nematistatique | |
CY1117395T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων |